AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has been given a $8.00 price objective by equities research analysts at Roth Capital in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price objective would suggest a potential upside of 272.09% from the stock’s current price.

A number of other brokerages have also recently issued reports on ACRX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Tuesday, October 3rd. Piper Jaffray Companies set a $3.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, July 25th. ValuEngine raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 1st. Finally, Royal Bank Of Canada set a $6.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $8.00.

Shares of AcelRx Pharmaceuticals (ACRX) traded down 59.81% during mid-day trading on Thursday, reaching $2.15. 24,274,300 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $3.80 and a 200 day moving average price of $2.97. The firm’s market cap is $97.57 million. AcelRx Pharmaceuticals has a 52-week low of $1.95 and a 52-week high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.01). The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $2.63 million. Analysts forecast that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current fiscal year.

WARNING: “Roth Capital Analysts Give AcelRx Pharmaceuticals, Inc. (ACRX) a $8.00 Price Target” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/12/roth-capital-analysts-give-acelrx-pharmaceuticals-inc-acrx-a-8-00-price-target.html.

In other news, CEO Vincent J. Angotti purchased 15,000 shares of the company’s stock in a transaction on Thursday, August 24th. The stock was acquired at an average price of $3.00 per share, with a total value of $45,000.00. Following the transaction, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at approximately $45,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total transaction of $53,751.69. Following the sale, the insider now directly owns 16,379 shares of the company’s stock, valued at approximately $86,644.91. The disclosure for this sale can be found here. Insiders have acquired a total of 37,000 shares of company stock valued at $112,280 in the last three months. 28.10% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its position in AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the period. Teachers Advisors LLC boosted its position in AcelRx Pharmaceuticals by 14.6% during the 4th quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. WealthTrust Axiom LLC boosted its position in AcelRx Pharmaceuticals by 50.0% during the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares during the period. Virtu KCG Holdings LLC boosted its position in AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Finally, LMR Partners LLP purchased a new stake in AcelRx Pharmaceuticals during the 2nd quarter valued at $319,000. 23.32% of the stock is owned by institutional investors and hedge funds.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.